Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
US FDA authorises phase 1 trial of ImmunityBio’s COVID-19 vaccine candidate hAd5
Ongoing development proceeding for oral, inhalational and intranasal administration of hAd5
US FDA approves KEYTRUDA from Merck for adults with relapsed or refractory cHL
KEYTRUDA is the first anti-PD-1 therapy approved for adult patients with relapsed or refractory cHL after frontline therapy
India is the Vice-Chair of OECD Working Group on GLP
India's leadership in GLP brings a greater recognition of our certification of quality for global businesses, said Prof Ashutosh…
Russia approves second COVID-19 vaccine
The vaccine, developed by the Vector Institute in Siberia, completed early-stage human trials last month but the results have not…
Gowda invites LatAm, Caribbean countries to invest in India’s pharma sector
There is a need to convert common interest between Indian and Latin American/Caribbean countries into a successful model of…
AuraVax Therapeutics partners with University of Houston for intranasal vaccine platform
AuraVax has the option to exclusively license patents covering this technology
Faceless assessment causes delay in customs clearance
Industry urges government to waive off demurrage charges
Lactiga and Mount Sinai sign pact to advance its patented biologic for COVID-19 treatment
The collaborative team secured an NIH R01 Emergency Award of $2 million dollars to expand this study
COVID-19 has made online learning a credible source of education
Romola Pinto, who leads the Rubicon Academy team and also heads the HR function at Rubicon Research, speaks about the…
Eli Lilly pauses trial of antibody drug for COVID-19 over safety concern
The company had said earlier this month that it was applying for EUA for the antibody-drug, LY-CoV555, for patients with mild to…